Untitled

doi:10.18632/oncotarget.v12i3

Cited by 2 publications

(1 citation statement)

References 90 publications

(138 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found that exosomal SK1 from ECs enhanced HSC migration, accompanied with upregulation of p-AKT ( 78 ). Additionally, sEVs from human cerebral ECs (hCEC) carrying abundant miR-214 could sensitize HCC cells towards oxaliplatin and sorafenib treatment through inhibition of splicing factor 3B subunit 3 (SF3B3) expression ( 79 ).…”

Section: Sevs From Stromal Cells and Hcc Stemnessmentioning

confidence: 99%

Extracellular vesicles and cancer stemness in hepatocellular carcinoma – is there a link?

Tian,

Lu,

2024

Front. Immunol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy, with high recurrence rates and notorious resistance to conventional chemotherapy. Cancer stemness refers to the stem-cell-like phenotype of cancer cells and has been recognized to play important roles in different aspects of hepatocarcinogenesis. Small extracellular vesicles (sEVs) are small membranous particles secreted by cells that can transfer bioactive molecules, such as nucleic acids, proteins, lipids, and metabolites, to neighboring or distant cells. Recent studies have highlighted the role of sEVs in modulating different aspects of the cancer stemness properties of HCC. Furthermore, sEVs derived from diverse cellular sources, such as cancer cells, stromal cells, and immune cells, contribute to the maintenance of the cancer stemness phenotype in HCC. Through cargo transfer, specific signaling pathways are activated within the recipient cells, thus promoting the stemness properties. Additionally, sEVs can govern the secretion of growth factors from non-cancer cells to further maintain their stemness features. Clinically, plasma sEVs may hold promise as potential biomarkers for HCC diagnosis and treatment prediction. Understanding the underlying mechanisms by which sEVs promote cancer stemness in HCC is crucial, as targeting sEV-mediated communication may offer novel strategies in treatment and improve patient outcome.

show abstract

Section: Sevs From Stromal Cells and Hcc Stemnessmentioning

confidence: 99%

Extracellular vesicles and cancer stemness in hepatocellular carcinoma – is there a link?

Tian,

Lu,

2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

The progress of optional targets and approaches to enhance efficacy of CAR-T for pancreatic ductal adenocarcinoma

Xie

2024

Third International Conference on Biological Engineering and Medical Science (ICBioMed2023)

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) constitutes the majority of pancreatic cancer which is one of the most lethal cancers all over the world. Due to the malignancy of PDAC with concealed property, the treatment choices were limited. Chimeric antigen receptor T cells (CAR-T) were applied to treat PDAC in clinical and preclinical trials to offer more opportunities. The burdens of CAR-T for PDAC such as tumor immunosuppressive microenvironment and off-tumor toxicity are being strived to address. Novel targets of CAR-T cells with multiple targeting, new designs of CAR and combination therapies give the treatment more options and possibility, which may contribute to improvement of CAR-T therapy for PDAC.

show abstract

Untitled

Abstract: Although numerous drugs seemingly extend healthspan in mice, only a few extend lifespan in mice and only one does it consistently. Some of them, alone or in combination, can be used in humans, without further clinical trials.

Cited by 2 publications

References 90 publications

Extracellular vesicles and cancer stemness in hepatocellular carcinoma – is there a link?

Extracellular vesicles and cancer stemness in hepatocellular carcinoma – is there a link?

The progress of optional targets and approaches to enhance efficacy of CAR-T for pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About